Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.12 Per Share
Wall Street analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to report earnings of ($0.12) per share for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from ($0.15) to ($0.08). Vanda Pharmaceuticals posted earnings of ($0.01) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1,100%. The company is scheduled to announce its next earnings report on Wednesday, February 21st.
According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year earnings of ($0.44) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.39). For the next financial year, analysts forecast that the company will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.72) to $0.04. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. The company had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $43.90 million. During the same period last year, the company posted ($0.01) EPS. Vanda Pharmaceuticals’s revenue was up 7.3% on a year-over-year basis.
Vanda Pharmaceuticals (VNDA) opened at $15.25 on Thursday. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $18.99. The stock has a market cap of $682.90, a PE ratio of -47.66 and a beta of 1.28.
Several hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC grew its stake in shares of Vanda Pharmaceuticals by 221.3% in the third quarter. Cubist Systematic Strategies LLC now owns 25,387 shares of the biopharmaceutical company’s stock worth $454,000 after acquiring an additional 17,485 shares during the period. University of Notre Dame DU Lac bought a new stake in shares of Vanda Pharmaceuticals in the third quarter worth approximately $2,824,000. Schwab Charles Investment Management Inc. grew its stake in shares of Vanda Pharmaceuticals by 2.5% in the third quarter. Schwab Charles Investment Management Inc. now owns 472,516 shares of the biopharmaceutical company’s stock worth $8,459,000 after acquiring an additional 11,647 shares during the period. Wells Fargo & Company MN grew its stake in shares of Vanda Pharmaceuticals by 112.2% in the third quarter. Wells Fargo & Company MN now owns 151,693 shares of the biopharmaceutical company’s stock worth $2,715,000 after acquiring an additional 80,209 shares during the period. Finally, Cadence Capital Management LLC bought a new stake in Vanda Pharmaceuticals during the third quarter valued at approximately $1,121,000. Hedge funds and other institutional investors own 88.43% of the company’s stock.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.